Search
Pergolide
go.drugbank.com/drugs/DB01186ApprovedVet approvedWithdrawnPergolide is a long-acting dopamine agonist approved in 1982 for the treatment of Parkinson’s Disease. … While the use of pergolide in humans is still approved in only some countries, pergolide is mainly used for veterinary purposes.
Categories: Heterocyclic Compounds with 4 or More RingsPanobinostat
go.drugbank.com/drugs/DB06603ApprovedInvestigationalPanobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. … Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexArbaclofen
go.drugbank.com/drugs/DB08891InvestigationalIt has also been investigated as a treatment for spasticity due to multiple sclerosis and spinal cord injury. … Arbaclofen was investigated as a treatment for gastroesophageal reflux disease (GERD); however, with disappointing results.
Ensifentrine
go.drugbank.com/drugs/DB16157ApprovedInvestigationalEnsifentrine is a first-in-class, selective dual inhibitor of the phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) enzymes. … [L50903] On June 26, 2024, the FDA announced the approval of an inhaled product of ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD) in adults, which allows the drug to be
Synonyms: 2-(9,10-DIMETHOXY-4-OXO-2-(2,4,6-TRIMETHYLPHENYL)IMINO-6,7-DIHYDROPYRIMIDO(6,1-A)ISOQUINOLIN-3-YL)ETHYLUREA, N-(2-((2E)-9,10-DIMETOXI-4-OXO-2-((2,4,6-TRIMETILFENIL)IMINO)-6,7-DIHIDRO-2H-PIRIMIDO(6,1-A)ISOQUINOLEIN-3(4H)-IL)ETIL)UREADFV890
go.drugbank.com/drugs/DB16461InvestigationalDFV890 is under investigation in multiple clinical trials for its efficacy, safety, and tolerability across various conditions: NCT06031844 (coronary heart disease with elevated hsCRP), NCT04886258 (symptomatic
Categories: Experimental Unapproved Treatments for COVID-19Bromotheophylline
go.drugbank.com/drugs/DB14018Approved[L1082] It is also approved by Health Canada to be used alone or in combination with [DB00316] in OTC products.[L1113] … Bromotheophylline is the active moiety of pamabrom, a mixture of 2-amino-2-methyl-propanol and bromotheophylline.
Categories: Drugs for Obstructive Airway DiseasesThalidomide
go.drugbank.com/drugs/DB01041ApprovedInvestigationalWithdrawnIt has been reintroduced and used for a number of inflammatory disorders and cancers. … A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects.
International brands: Pro-ban MDeflazacort
go.drugbank.com/drugs/DB11921ApprovedDeflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). … [L6694] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dystrophin gene, which is important for muscle function.
Categories: Corticosteroids for Systemic Use, Corticosteroids for Systemic Use, PlainLinerixibat
go.drugbank.com/drugs/DB11729ApprovedInvestigationalLinerixibat is a first-in-class and small-molecule inhibitor of the ileal bile acid transporter (IBAT). … [A275481, A275482] On March 19, 2026, linerixibat was approved by the FDA for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC).
Valoctocogene roxaparvovec
go.drugbank.com/drugs/DB15561ApprovedInvestigationalWithdrawn[L43282,A252807] Valoctocogene roxaparvovec was approved by EMA in September 2022 and is indicated for the treatment of severe hemophilia A. It is not approved for use in the United States. … [L43292] Hemophilia A treatments such as prophylactic regimens of exogenous factor VIII or [emicizumab] improve the clinical outcomes of patients but do not eliminate breakthrough bleeding.